Company / Cash & Equivalents
BioXcel Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$28.4M
FY2025
5-year range
$28.4M / $193.7M
FY2022-FY2025
Trend
-4.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $194M in FY2022 to $28M in FY2025.
Based on SEC 10-K filings.
$28M in FY2025 with a 3-year CAGR of -47.3%.
Declined from $65M to $28M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -47.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- BioXcel Therapeutics, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -47.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 4.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.4M | -4.8% |
| FY2024 | $29.9M | -54.2% |
| FY2023 | $65.2M | -66.3% |
| FY2022 | $193.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026